CA2609389A1 - Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment - Google Patents

Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment Download PDF

Info

Publication number
CA2609389A1
CA2609389A1 CA002609389A CA2609389A CA2609389A1 CA 2609389 A1 CA2609389 A1 CA 2609389A1 CA 002609389 A CA002609389 A CA 002609389A CA 2609389 A CA2609389 A CA 2609389A CA 2609389 A1 CA2609389 A1 CA 2609389A1
Authority
CA
Canada
Prior art keywords
compound
cancer
formula
combination
akt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609389A
Other languages
English (en)
French (fr)
Inventor
Urban Scheuring
Ingo Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare Ag
Urban Scheuring
Ingo Bernard
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Urban Scheuring, Ingo Bernard, Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Healthcare Ag
Publication of CA2609389A1 publication Critical patent/CA2609389A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002609389A 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment Abandoned CA2609389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011477.6 2005-05-27
EP05011477 2005-05-27
PCT/EP2006/004524 WO2006125540A1 (en) 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Publications (1)

Publication Number Publication Date
CA2609389A1 true CA2609389A1 (en) 2006-11-30

Family

ID=36636325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609389A Abandoned CA2609389A1 (en) 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Country Status (11)

Country Link
EP (1) EP1888067A1 (ja)
JP (1) JP2008542214A (ja)
KR (1) KR20080018908A (ja)
CN (1) CN101257903A (ja)
AU (1) AU2006251429A1 (ja)
BR (1) BRPI0610048A2 (ja)
CA (1) CA2609389A1 (ja)
IL (1) IL187508A0 (ja)
MX (1) MX2007014726A (ja)
RU (1) RU2007148266A (ja)
WO (1) WO2006125540A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE384264T1 (de) 2003-05-20 2008-02-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe mit kinasehemmender wirkung
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
EP1962841A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating virus infections
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP5885012B2 (ja) * 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
EP2114403A2 (en) * 2007-01-19 2009-11-11 Bayer Healthcare, LLC Treatment of cancers having resistance to chemotherapeutic agents
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2296641A1 (en) * 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
CA2763589A1 (en) 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用
CN102643229A (zh) * 2012-01-17 2012-08-22 湖南有色凯铂生物药业有限公司 N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用
CN102885814A (zh) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 一种化合物及其作为抗癌药物的应用
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
WO2014145386A2 (en) 2013-03-15 2014-09-18 University Of Florida Research Foundation Incorporated Novel allosteric inhibitors of thymidylate synthase
NZ731518A (en) * 2014-12-17 2019-03-29 Pfizer Formulations of a pi3k/mtor-inhibitor for intravenous administration
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
CN104906086A (zh) * 2015-06-24 2015-09-16 安徽四正医药科技有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
KR102544163B1 (ko) * 2022-08-10 2023-06-16 주식회사 하이밸 소음저감형 유량 및 압력 조절용 감압밸브
CN115804844B (zh) * 2022-09-26 2024-05-10 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) * 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions

Also Published As

Publication number Publication date
IL187508A0 (en) 2008-06-05
WO2006125540A1 (en) 2006-11-30
JP2008542214A (ja) 2008-11-27
CN101257903A (zh) 2008-09-03
MX2007014726A (es) 2008-02-14
KR20080018908A (ko) 2008-02-28
EP1888067A1 (en) 2008-02-20
BRPI0610048A2 (pt) 2010-05-25
AU2006251429A1 (en) 2006-11-30
RU2007148266A (ru) 2009-07-10

Similar Documents

Publication Publication Date Title
US20090192127A1 (en) Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
CA2609389A1 (en) Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
US20090306020A1 (en) Combination therapy comprising diaryl ureas for treating diseases
JP6342392B2 (ja) 置換型ピラゾロン化合物及び使用方法
JP6542808B2 (ja) ラパマイシン誘導体、並びにその調製方法、医薬組成物及び使用
US20080045589A1 (en) Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
JP2016199556A (ja) Ｎａｍｐｔを阻害するための新規な化合物および組成物
PL220952B1 (pl) 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
KR20120034729A (ko) 야누스 키나제 억제제 화합물 및 방법
EP2496578A2 (en) Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same
US20130310374A1 (en) Substituted Imidazoquinoline Derivatives
EP2595628A1 (en) Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2017045615A1 (zh) 吡啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
EP3628669A1 (en) Novel compounds as nadph oxidase inhibitors
EP3108883A1 (en) Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
JP4365586B2 (ja) 血管形成阻害活性を有するフタラジン誘導体
CN101180055A (zh) 用于治疗疾病的包含二芳基脲的组合治疗
JP2022506289A (ja) インダゾールキナーゼ阻害剤及びその使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131205